As a treatment for moderate to severe plaque psoriasis (a skin disease characterized by red, scaly patches on certain areas of the body), ustekinumab is recommended for adults and children 6 years or older. This medication belongs to the monoclonal antibody class. Various therapies are available to treat psoriatic arthritis in adults, such as ustekinumab used alone or with methotrexate (otrexup, trexall). In psoriatic arthritis, the skin becomes scaly and painful, and there is swelling in the joints. Aside from that, it can also be used to treat Crohn's disease and ulcerative colitis. In contrast, Crohn's disease occurs when the body attacks the lining of the digestive tract, resulting in pain, diarrhea, weight loss, and fever. It works by stopping the action of certain cells in the body that cause symptoms of psoriatic arthritis, plaque psoriasis, ulcerative colitis, and Crohn's disease. In addition to nausea, headaches, fatigue, and sneezing, other common side effects include joint pain, runny noses, stuffed noses, or sneezing. Seizures, vision changes, difficulty breathing, among other serious side effects, may also occur. This is a type of biologic disease-modifying antirheumatic medication (bDMARD) used to treat inflammatory diseases caused by activation of the IL-12 and IL-23 pathways.
This medication prevents certain cells in the body from causing symptoms of plaque psoriasis, Crohn's disease, psoriatic arthritis, and ulcerative colitis. Ustekinumab is the brand name of the antibody Stelara. Globally, the prevalence of psoriasis patients is a major driving force behind the market's growth. The market growth rate of ustekinumab is also influenced by rising healthcare expenditures. Additionally, the growing geriatric population and the increase in clinical trial studies will contribute to the expansion of the ustekinumab market. Increasing government initiatives and increasing awareness will also positively impact the market growth rate. In addition to the increase in demand from different end-use industries, ustekinumab market growth will be cushioned by the increase in supply. A rise in disposable income and rapid urbanization will also increase the market growth rate during the forecast period mentioned above. The ustekinumab market is expected to grow over the forecast period due to changing lifestyles and rising consumption of alcohol and tobacco. Furthermore, the growth in research and development activities and the emergence of new markets will provide beneficial opportunities for the ustekinumab market. In addition, the continuous growth of the economy along with the improvement of healthcare infrastructure will provide new growth opportunities for the market.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Ustekinumab Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Ustekinumab Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.